Recent advancements include the superior performance of CCR4-IL2 immunotoxin (Wang et al., 2023), RT39 peptide therapy (Habault et al., 2022), novel drug NT1721 (Lin et al., 2021), JAK3-INSL3 fusion transcripts (Velatooru et al., 2023), anti-CCR4 CAR T cells (Watanabe et al., 2023), universal CD2 CAR-T therapy (Xiang et al., 2023) and the antibody-drug conjugate SGN-CD70A (Wu et al., 2022) have further expanded the therapeutic research landscape for CTCL. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.